You’ve Been Warned!
Just this past Friday the Food and Drug Adminstration ( FDA) said that SGLT2 (sodium-glucose contransporter-2) inhibitors, including Empaglifliozin (Jardiance), Dapagliflozin (Farxiga), and Canagliflozin (Invokana) will need new warnings about the risks of developing ketoacidosis, urinary tract infections that require hospitalization and other serious illnesses related to taking the medications.
More than 70 cases have been reported to the FDA, with 19 of those being “life-threatening” (MedPageToday.com).
SGLT2 inhibitors are used to treat Type I and Type II diabetes by excreting glucose in the urine which then lowers blood levels. They have only been approved for a couple of years and have already become plagued with reports of serious side effects. These reports are on the rise.
The “life-threatening” cases of urinary tract infections occurred in patients who took Invokana and Farxiga, while Jardiance was not included. Though no cases were fatal, four of them required intensive care and all of the victims were hospitalized.
Most patients who develop ketoacidosis do so at an average of 43 days after taking the medication, though it can develop the day after starting on your prescription, or up to a year thereafter. Long term effects have not been determined.
FDA Urges Doctors to be Vigilant
The FDA is urging doctors to consider the risks before prescribing SGLT2 inhibitors. They should watch for patients complaining of the symptoms of ketoacidosis and evaluate them carefully when necessary.
They also said the drug should not be stopped if ketoacidosis is suspected.
If you have suffered from adverse side effects after taking Invokana or another SLGT2 inhibitor we would like to speak with you. We are currently investigating and accepting claims of ketoacidosis, kidney failure and heart attacks associated with SLGT2 inhibitor use. Contact us today for a free confidential case evaluation with experienced Invokana lawyers who are here to help. You may be entitled to financial compensation.
By: Kay Van Wey | January 26th, 2016